Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With <i>nab</i>-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer.
第一作者:
Jonathan W,Goldman
第一单位:
David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, United States.
作者:
DOI
10.3389/fonc.2019.01256
PMID
31850192
发布时间
2020-10-01
- 浏览0
Frontiers in oncology
1256页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文